| Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial MZH Farooqui, J Valdez, S Martyr, G Aue, N Saba, CU Niemann, ... The lancet oncology 16 (2), 169-176, 2015 | 482 | 2015 |
| Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia W Fiskus, N Saba, M Shen, M Ghias, J Liu, SD Gupta, L Chauhan, R Rao, ... Cancer research 74 (9), 2520-2532, 2014 | 241 | 2014 |
| Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study IE Ahn, MZH Farooqui, X Tian, J Valdez, C Sun, S Soto, J Lotter, S Housel, ... Blood, The Journal of the American Society of Hematology 131 (21), 2357-2366, 2018 | 214 | 2018 |
| Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study SEM Herman, CU Niemann, M Farooqui, J Jones, RZ Mustafa, A Lipsky, ... Leukemia 28 (11), 2188-2196, 2014 | 213 | 2014 |
| A smartphone-read ultrasensitive and quantitative saliva test for COVID-19 B Ning, T Yu, S Zhang, Z Huang, D Tian, Z Lin, A Niu, N Golden, ... Science advances 7 (2), eabe3703, 2021 | 197 | 2021 |
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib AH Lipsky, MZH Farooqui, X Tian, S Martyr, AM Cullinane, K Nghiem, ... Haematologica 100 (12), 1571, 2015 | 178 | 2015 |
| Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma NS Saba, D Liu, SEM Herman, C Underbayev, X Tian, D Behrend, ... Blood, The Journal of the American Society of Hematology 128 (1), 82-92, 2016 | 166 | 2016 |
| Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood TM Herndon, SS Chen, NS Saba, J Valdez, C Emson, M Gatmaitan, ... Leukemia 31 (6), 1340-1347, 2017 | 134 | 2017 |
| Liposome-mediated detection of SARS-CoV-2 RNA-positive extracellular vesicles in plasma B Ning, Z Huang, BM Youngquist, JW Scott, A Niu, CM Bojanowski, ... Nature nanotechnology 16 (9), 1039-1044, 2021 | 98 | 2021 |
| A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era HR Robinson, J Qi, EM Cook, C Nichols, EL Dadashian, C Underbayev, ... Blood, The Journal of the American Society of Hematology 132 (5), 521-532, 2018 | 98 | 2018 |
| Bortezomib in plasmablastic lymphoma: a case report and review of the literature NS Saba, D Dang, J Saba, C Cao, M Janbain, B Maalouf, H Safah Oncology Research and Treatment 36 (5), 287-291, 2013 | 55 | 2013 |
| Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia C Bitar, MZH Farooqui, J Valdez, NS Saba, S Soto, A Bray, G Marti, ... JAMA dermatology 152 (6), 698-701, 2016 | 51 | 2016 |
| MALT1 inhibition is efficacious in both naive and ibrutinib-resistant chronic lymphocytic leukemia NS Saba, DH Wong, G Tanios, JR Iyer, P Lobelle-Rich, EL Dadashian, ... Cancer research 77 (24), 7038-7048, 2017 | 47 | 2017 |
| Cancer and COVID-19: analysis of patient outcomes M Aboueshia, MH Hussein, AS Attia, A Swinford, P Miller, M Omar, ... Future Oncology 17 (26), 3499-3510, 2021 | 44 | 2021 |
| Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia LM Saleh, W Wang, SEM Herman, NS Saba, V Anastas, E Barber, ... Leukemia 31 (2), 340-349, 2017 | 40 | 2017 |
| Chemotherapy-induced hyperpigmentation of the tongue M Blaya, N Saba N Engl J Med 365 (10), e20, 2011 | 28 | 2011 |
| COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma A Niu, A McDougal, B Ning, F Safa, A Luk, DM Mushatt, A Nachabe, ... Bone marrow transplantation 55 (12), 2354-2356, 2020 | 27 | 2020 |
| Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation M Farooqui, JN Lozier, J Valdez, N Saba, A Wells, S Soto, D Liu, G Aue, ... Blood 120 (21), 1789, 2012 | 25 | 2012 |
| Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs M Shen, Y Zhang, N Saba, CP Austin, A Wiestner, DS Auld PloS one 8 (9), e75252, 2013 | 24 | 2013 |
| The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia C Sun, YC Chen, A Martinez Zurita, MJ Baptista, S Pittaluga, D Liu, ... Blood Advances 7 (1), 145-158, 2023 | 23 | 2023 |
Sarah E. M. HermanThe Johns Hopkins University Applied Physics LaboratoryVerified email at jhuapl.edu
